OZOren Zimhony

Oren Zimhony

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Oren Zimhony has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Jacob Grunwald

    Structural Proteomics Unit, Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, 7610001, Israel

    2 shared publications
  • Shira Albeck

    Structural Proteomics Unit, Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, 7610001, Israel

    2 shared publications
  • Yoav Peleg

    Structural Proteomics Unit, Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, 7610001, Israel

    2 shared publications
  • Zippora Shakked

    Department of Structural Biology, Weizmann Institute of Science, Rehovot, 7610001, Israel

    2 shared publications
  • Alaa Atamna

    Rabin Medical Medical Center, Petah-Tiqva 4910002, Israel

    1 shared publication
  • Alon Schwartz

    Department of Structural Biology, Weizmann Institute of Science, Rehovot, Israel

    1 shared publication

Latest Publications

  • Open Access

    Invasive Fungal Diseases in Hospitalized Patients with COVID-19 in Israel: A Multicenter Cohort Study

    by Meital Elbaz, Maya Korem, Oshrat Ayalon, Yonit Wiener-Well, Yael Shachor-Meyouhas, Regev Cohen, Jihad Bishara, Alaa Atamna, Tal Brosh-Nissimov, Nir Maaravi, et al.

    Highly variable estimates of COVID-19-associated fungal diseases (IFDs) have been reported. We aimed to determine the incidence of clinically important fungal diseases in hospitalized COVID-19 patients during the first year of the pandemic. We performed a multicenter survey of IFDs among patients hospitalized with COVID-19 in 13 hospitals in Israel between February 2020 and May 2021. COVID-19-associated pulmonary mold disease (PMD) and invasive candidiasis (IC) were defined using ECMM/ISHAM and EORTC/MSG criteria, respectively. Overall rates of IC and PMD among patients with critical COVID-19 were 10.86 and 10.20 per 1000 admissions, respectively, with significant variability among medical centers. PMD rates were significantly lower in centers where galactomannan was a send-out test versus centers with on-site testing (p = 0.035). The 30-day mortality rate was 67.5% for IC and 57.5% for PMD. Treatment with an echinocandin for IC or an extended-spectrum azole for PMD was associated with significantly lower mortality rates (adjusted hazard ratio [95% confidence interval], 0.26 [0.07–0.91] and 0.23 [0.093–0.57], respectively). In this multicenter national survey, variable rates of PMD were associated with on-site galactomannan testing, suggesting under-detection in sites lacking this capacity. COVID-19-related IFDs were associated with high mortality rates, which were reduced with appropriate antifungal therapy.


  • Open Access

    Structure of Type-I Mycobacterium tuberculosis fatty acid synthase at 3.3 Å resolution

    by Nadav Elad, Szilvia Baron, Yoav Peleg, Shira Albeck, Jacob Grunwald, Gal Raviv, Zippora Shakked, Oren Zimhony, Ron Diskin

    Tuberculosis (TB) is a devastating and rapidly spreading disease caused by Mycobacterium tuberculosis (Mtb). Therapy requires prolonged treatment with a combination of multiple agents and interruptions in the treatment regimen result in emergence and spread of multi-drug resistant (MDR) Mtb strains. MDR Mtb poses a significant global health problem, calling for urgent development of novel drugs to combat TB. Here, we report the 3.3 Å resolution structure of the ~2 MDa type-I fatty acid synthase (FAS-I) from Mtb, determined by single particle cryo-EM. Mtb FAS-I is an essential enzymatic complex that contributes to the virulence of Mtb, and thus a prime target for anti-TB drugs. The structural information for Mtb FAS-I we have obtained enables computer-based drug discovery approaches, and the resolution achieved by cryo-EM is sufficient for elucidating inhibition mechanisms by putative small molecular weight inhibitors.


  • Open Access

    Expression of a recombinant, 4’-Phosphopantetheinylated, active M. tuberculosis Fatty acid Synthase I in E. coli

    by Szilvia Baron, Yoav Peleg, Jacob Grunwald, David Morgenstern, Nadav Elad, Moshe Peretz, Shira Albeck, Yishai Levin, John T. Welch, Kim A. Deweerd, et al.

    Fatty acid synthase 1 (FAS I) from Mycobacterium. tuberculosis ( Mtb ) is an essential protein and a promising drug target. FAS I is a multi-functional, multi-domain protein that is organized as a large (1.9 MDa) homohexameric complex. Acyl intermediates produced during fatty acid elongation are attached covalently to an acyl carrier protein (ACP) domain. This domain is activated by the transfer of a 4’-Phosphopantetheine (4’-PP, also termed P-pant) group from CoA to ACP catalyzed by a 4’-PP transferase, termed acyl carrier protein synthase (AcpS). In order to obtain an activated FAS I in E. coli , we transformed E. coli with tagged Mtb fas1 and acpS genes encoded by a separate plasmid. We induced the expression of Mtb FAS I following induction of AcpS expression. FAS I was purified by Strep-Tactin affinity chromatography. Activation of Mtb FAS I was confirmed by the identification of a bound P-pant group on serine at position 1808 by mass spectrometry. The purified FAS I displayed biochemical activity shown by spectrophotometric analysis of NADPH oxidation and by CoA production, using the Ellman reaction. The purified Mtb FAS I forms a hexameric complex shown by negative staining and cryo-EM. Purified hexameric and active Mtb FAS I is required for binding and drug inhibition studies and for structurefunction analysis of this enzyme. This relatively simple and short procedure for Mtb FAS I production should facilitate studies of this enzyme.